Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CRON vs IIPR vs CGC vs REFI vs ACB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-34.4%
IIPR
Innovative Industrial Properties, Inc.

REIT - Industrial

Real EstateNYSE • US
Market Cap$1.62B
5Y Perf.-78.5%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-98.7%
REFI
Chicago Atlantic Real Estate Finance, Inc.

REIT - Mortgage

Real EstateNASDAQ • US
Market Cap$245M
5Y Perf.-30.2%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$195M
5Y Perf.-93.7%

CRON vs IIPR vs CGC vs REFI vs ACB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CRON logoCRON
IIPR logoIIPR
CGC logoCGC
REFI logoREFI
ACB logoACB
IndustryDrug Manufacturers - Specialty & GenericREIT - IndustrialDrug Manufacturers - Specialty & GenericREIT - MortgageDrug Manufacturers - Specialty & Generic
Market Cap$981M$1.62B$122M$245M$195M
Revenue (TTM)$193M$263M$294M$44M$361M
Net Income (TTM)$-9M$120M$-327M$4.87B$41M
Gross Margin32.5%60.3%22.8%95.6%62.7%
Operating Margin-1.5%46.7%-24.1%18.4%13.3%
Forward P/E34.3x13.2x6.4x164.2x
Total Debt$2M$394M$348M$98M$104M
Cash & Equiv.$792M$48M$114M$15M$184M

CRON vs IIPR vs CGC vs REFI vs ACBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CRON
IIPR
CGC
REFI
ACB
StockDec 21May 26Return
Cronos Group Inc. (CRON)10065.6-34.4%
Innovative Industri… (IIPR)10021.5-78.5%
Canopy Growth Corpo… (CGC)1001.3-98.7%
Chicago Atlantic Re… (REFI)10069.8-30.2%
Aurora Cannabis Inc. (ACB)1006.3-93.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: CRON vs IIPR vs CGC vs REFI vs ACB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: REFI leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Cronos Group Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. IIPR and ACB also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CRON
Cronos Group Inc.
The Long-Run Compounder

CRON is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.

  • 14.6% 10Y total return vs IIPR's 436.4%
  • Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
  • 64.4% revenue growth vs IIPR's -13.8%
  • +38.9% vs ACB's -25.3%
Best for: long-term compounding and sleep-well-at-night
IIPR
Innovative Industrial Properties, Inc.
The Real Estate Income Play

IIPR ranks third and is worth considering specifically for dividends.

  • 13.5% yield, 9-year raise streak, vs REFI's 100.0%, (3 stocks pay no dividend)
Best for: dividends
CGC
Canopy Growth Corporation
The Healthcare Pick

Among these 5 stocks, CGC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
REFI
Chicago Atlantic Real Estate Finance, Inc.
The Real Estate Income Play

REFI carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 1 yrs, beta 0.69, yield 100.0%
  • Beta 0.69, yield 100.0%, current ratio 0.28x
  • Lower P/E (6.4x vs 164.2x)
  • 109.7% margin vs CGC's -111.0%
Best for: income & stability and defensive
ACB
Aurora Cannabis Inc.
The Growth Play

ACB is the clearest fit if your priority is growth exposure.

  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • 5.2% ROA vs CGC's -29.5%, ROIC 0.7% vs -10.2%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs IIPR's -13.8%
ValueREFI logoREFILower P/E (6.4x vs 164.2x)
Quality / MarginsREFI logoREFI109.7% margin vs CGC's -111.0%
Stability / SafetyREFI logoREFIBeta 0.69 vs CGC's 1.90, lower leverage
DividendsIIPR logoIIPR13.5% yield, 9-year raise streak, vs REFI's 100.0%, (3 stocks pay no dividend)
Momentum (1Y)CRON logoCRON+38.9% vs ACB's -25.3%
Efficiency (ROA)ACB logoACB5.2% ROA vs CGC's -29.5%, ROIC 0.7% vs -10.2%

CRON vs IIPR vs CGC vs REFI vs ACB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000
IIPRInnovative Industrial Properties, Inc.

Segment breakdown not available.

CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
REFIChicago Atlantic Real Estate Finance, Inc.

Segment breakdown not available.

ACBAurora Cannabis Inc.

Segment breakdown not available.

CRON vs IIPR vs CGC vs REFI vs ACB — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCRONLAGGINGACB

Income & Cash Flow (Last 12 Months)

REFI leads this category, winning 3 of 6 comparable metrics.

ACB is the larger business by revenue, generating $361M annually — 8.1x REFI's $44M. REFI is the more profitable business, keeping 109.7% of every revenue dollar as net income compared to CGC's -111.0%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
RevenueTrailing 12 months$193M$263M$294M$44M$361M
EBITDAEarnings before interest/tax-$810,000$197M-$32M$8M$71M
Net IncomeAfter-tax profit-$9M$120M-$327M$4.9B$41M
Free Cash FlowCash after capex-$163,766$144M-$86M$3.2B-$31M
Gross MarginGross profit ÷ Revenue+32.5%+60.3%+22.8%+95.6%+62.7%
Operating MarginEBIT ÷ Revenue-1.5%+46.7%-24.1%+18.4%+13.3%
Net MarginNet income ÷ Revenue-4.9%+45.6%-111.0%+109.7%+11.2%
FCF MarginFCF ÷ Revenue-0.1%+54.7%-29.3%+71.8%-8.7%
Rev. Growth (YoY)Latest quarter vs prior year+2.0%-3.8%+20.9%-100.0%+6.8%
EPS Growth (YoY)Latest quarter vs prior year-100.0%-1.0%+83.8%-51.1%-94.5%
REFI leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

CGC leads this category, winning 3 of 6 comparable metrics.

At 6.9x trailing earnings, REFI trades at a 96% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than IIPR's 9.9x.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
Market CapShares × price$981M$1.6B$122M$245M$195M
Enterprise ValueMkt cap + debt − cash$190M$2.0B$293M$328M$136M
Trailing P/EPrice ÷ TTM EPS14.40x-0.28x6.92x164.21x
Forward P/EPrice ÷ next-FY EPS est.34.27x13.17x6.41x
PEG RatioP/E ÷ EPS growth rate3.85x
EV / EBITDAEnterprise value multiple9.91x9.12x6.73x
Price / SalesMarket cap ÷ Revenue5.07x6.08x0.62x3.88x0.77x
Price / BookPrice ÷ Book value/share0.90x0.87x0.34x0.81x0.43x
Price / FCFMarket cap ÷ FCF9.26x0.01x
CGC leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — CRON and ACB each lead in 3 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-43 for CGC. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs IIPR's 4/9, reflecting strong financial health.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
ROE (TTM)Return on equity-0.9%+6.4%-43.1%+6.4%+7.2%
ROA (TTM)Return on assets-0.8%+5.1%-29.5%+4.5%+5.2%
ROICReturn on invested capital-0.8%+4.3%-10.2%+6.9%+0.7%
ROCEReturn on capital employed-0.3%+5.8%-12.4%+9.3%+0.7%
Piotroski ScoreFundamental quality 0–964557
Debt / EquityFinancial leverage0.00x0.21x0.72x0.32x0.17x
Net DebtTotal debt minus cash-$790M$346M$235M$83M-$80M
Cash & Equiv.Liquid assets$792M$48M$114M$15M$184M
Total DebtShort + long-term debt$2M$394M$348M$98M$104M
Interest CoverageEBIT ÷ Interest expense6.67x-7.79x4.77x6.27x
Evenly matched — CRON and ACB each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CRON leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in REFI five years ago would be worth $12,468 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, CRON leads with a +38.9% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors CRON at 8.9% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
YTD ReturnYear-to-date-4.8%+18.3%-5.0%-1.4%-21.0%
1-Year ReturnPast 12 months+38.9%+20.3%-12.4%-7.9%-25.3%
3-Year ReturnCumulative with dividends+29.1%+14.1%-91.4%+25.7%-47.2%
5-Year ReturnCumulative with dividends-66.6%-50.0%-99.6%+24.7%-96.1%
10-Year ReturnCumulative with dividends+1457.6%+436.4%-94.3%+24.7%-92.0%
CAGR (3Y)Annualised 3-year return+8.9%+4.5%-55.9%+7.9%-19.2%
CRON leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — IIPR and REFI each lead in 1 of 2 comparable metrics.

REFI is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than CGC's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 92.2% from its 52-week high vs CGC's 47.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
Beta (5Y)Sensitivity to S&P 5000.98x0.92x1.90x0.69x1.81x
52-Week HighHighest price in past year$3.43$61.40$2.38$15.20$6.67
52-Week LowLowest price in past year$1.84$44.58$0.84$10.74$3.07
% of 52W HighCurrent price vs 52-week peak+74.9%+92.2%+47.5%+76.4%+51.4%
RSI (14)Momentum oscillator 0–10049.359.352.958.152.2
Avg Volume (50D)Average daily shares traded1.4M303K10.4M167K979K
Evenly matched — IIPR and REFI each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — IIPR and REFI each lead in 1 of 2 comparable metrics.

Analyst consensus: CRON as "Hold", IIPR as "Hold", CGC as "Hold", REFI as "Buy", ACB as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -22.3% for IIPR (target: $44). For income investors, REFI offers the higher dividend yield at 100.00% vs IIPR's 13.46%.

MetricCRON logoCRONCronos Group Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…REFI logoREFIChicago Atlantic …ACB logoACBAurora Cannabis I…
Analyst RatingConsensus buy/hold/sellHoldHoldHoldBuyHold
Price TargetConsensus 12-month target$2.30$44.00$14.47$14.00$5.92
# AnalystsCovering analysts151126614
Dividend YieldAnnual dividend ÷ price+13.5%+100.0%
Dividend StreakConsecutive years of raises91
Dividend / ShareAnnual DPS$7.62$2045.71
Buyback YieldShare repurchases ÷ mkt cap+1.0%+1.2%0.0%0.0%0.0%
Evenly matched — IIPR and REFI each lead in 1 of 2 comparable metrics.
Key Takeaway

REFI leads in 1 of 6 categories (Income & Cash Flow). CGC leads in 1 (Valuation Metrics). 3 tied.

Best OverallCronos Group Inc. (CRON)Leads 1 of 6 categories
Loading custom metrics...

CRON vs IIPR vs CGC vs REFI vs ACB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CRON or IIPR or CGC or REFI or ACB a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). Chicago Atlantic Real Estate Finance, Inc. (REFI) offers the better valuation at 6. 9x trailing P/E (6. 4x forward), making it the more compelling value choice. Analysts rate Chicago Atlantic Real Estate Finance, Inc. (REFI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CRON or IIPR or CGC or REFI or ACB?

On trailing P/E, Chicago Atlantic Real Estate Finance, Inc.

(REFI) is the cheapest at 6. 9x versus Aurora Cannabis Inc. at 164. 2x. On forward P/E, Chicago Atlantic Real Estate Finance, Inc. is actually cheaper at 6. 4x.

03

Which is the better long-term investment — CRON or IIPR or CGC or REFI or ACB?

Over the past 5 years, Chicago Atlantic Real Estate Finance, Inc.

(REFI) delivered a total return of +24. 7%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus CGC's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CRON or IIPR or CGC or REFI or ACB?

By beta (market sensitivity over 5 years), Chicago Atlantic Real Estate Finance, Inc.

(REFI) is the lower-risk stock at 0. 69β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 176% more volatile than REFI relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — CRON or IIPR or CGC or REFI or ACB?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CRON or IIPR or CGC or REFI or ACB?

Chicago Atlantic Real Estate Finance, Inc.

(REFI) is the more profitable company, earning 57. 1% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps 57. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REFI leads at 57. 1% versus -43. 5% for CGC. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CRON or IIPR or CGC or REFI or ACB more undervalued right now?

On forward earnings alone, Chicago Atlantic Real Estate Finance, Inc.

(REFI) trades at 6. 4x forward P/E versus 34. 3x for Cronos Group Inc. — 27. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.

08

Which pays a better dividend — CRON or IIPR or CGC or REFI or ACB?

In this comparison, REFI (100.

0% yield), IIPR (13. 5% yield) pay a dividend. CRON, CGC, ACB do not pay a meaningful dividend and should not be held primarily for income.

09

Is CRON or IIPR or CGC or REFI or ACB better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CRON and IIPR and CGC and REFI and ACB?

These companies operate in different sectors (CRON (Healthcare) and IIPR (Real Estate) and CGC (Healthcare) and REFI (Real Estate) and ACB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRON is a small-cap high-growth stock; IIPR is a small-cap deep-value stock; CGC is a small-cap quality compounder stock; REFI is a small-cap high-growth stock; ACB is a small-cap high-growth stock. IIPR, REFI pay a dividend while CRON, CGC, ACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Stocks Like

IIPR

Dividend Mega-Cap Quality

  • Sector: Real Estate
  • Market Cap > $100B
  • Net Margin > 27%
  • Dividend Yield > 5.3%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

REFI

Dividend Mega-Cap Quality

  • Sector: Real Estate
  • Market Cap > $100B
  • Net Margin > 6583%
  • Dividend Yield > 40.0%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CRON and IIPR and CGC and REFI and ACB on the metrics below

Revenue Growth>
%
(CRON: 201.3% · IIPR: -3.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.